Biomarkers for Alzheimer’s disease beyond amyloid and tau

@article{Zetterberg2019BiomarkersFA,
  title={Biomarkers for Alzheimer’s disease beyond amyloid and tau},
  author={Henrik Zetterberg and Jonathan M. Schott},
  journal={Nature Medicine},
  year={2019},
  volume={25},
  pages={201-203}
}
Two new biomarkers for Alzheimer’s disease include one in the blood that relates to neurodegeneration and another that reflects blood–brain barrier dysfunction and is identifiable in cerebrospinal fluid analysis. 
Alzheimer's disease research: past approaches and future directions
Background: Three decades after the amyloid cascade hypothesis was first proposed, research into discovery of effective treatments for Alzheimer's disease has not yet produced any disease-modifying...
BIOMARKERS AS MEDIATORS USED IN ALZHEIMER'S DISEASE
Over the last decade, biomarkers have significantly improved our understanding of the pathophysiology of Alzheimer disease (AD) and provided valuable tools to examine different disease mechanisms and
Biomarkers: Our Path Towards a Cure for Alzheimer Disease
TLDR
The integration of biomarker data with clinical, cognitive, and imaging domains through a systems biology approach will be essential to adequately capture the molecular, genetic, and pathological heterogeneity of AD and its spatiotemporal evolution over time.
Whole Blood Expression Pattern of Inflammation and Redox Genes in Mild Alzheimer’s Disease
TLDR
It is found that the master regulators of inflammation and redox homeostasis, NFκB and NRF2, were significantly disturbed in the blood of AD patients, as well as several zinc finger and helix-loop-helix transcription factors.
Disentangling Heterogeneity in Alzheimer's Disease: Two Empirically-Derived Subtypes.
TLDR
Cognitive profiles showed longitudinal stability with corresponding patterns of cortical atrophy, despite nearly identical rates of progression to AD dementia, with potential implications for preventative efforts.
A unified model of dementias and age‐related neurodegeneration
  • M. Fossel
  • Medicine
    Alzheimer's & dementia : the journal of the Alzheimer's Association
  • 2020
TLDR
A novel model is presented to explain the relationships between age-related neurodegenerative disorders (eg, dementias) and the underlying molecular mechanisms of the aging process and is intended to provoke discussion and provide a point of departure.
Nanomaterial-based Optical and Electrochemical Biosensors for Amyloid beta and Tau: Potential for early diagnosis of Alzheimer’s Disease
TLDR
The study has identified the potential application of advanced biosensors as standardized clinical diagnostic tools for AD, evolving the way for new and efficient AD control with minimum economic and social burden.
Impact of HMGB1, RAGE, and TLR4 in Alzheimer’s Disease (AD): From Risk Factors to Therapeutic Targeting
TLDR
The contribution of HMGB1 and its receptor signaling in neuroinflammation and AD pathogenesis is discussed, providing evidence of its beneficial effects upon therapeutic targeting.
c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimer’s Diseases
TLDR
Biological aspects of JNK, focusing on JNK3 and how it relates to AD are presented, and the recent development of inhibitors that could be used in AD treatment since several drugs/compounds in phase III clinical trials failed are explored.
...
1
2
3
...

References

SHOWING 1-10 OF 26 REFERENCES
Update on biomarkers for amyloid pathology in Alzheimer's disease.
TLDR
The current clinical, diagnostic and research state of biomarkers for A β pathology is discussed and the current application of blood-based markers to assess Aβ pathology is explored.
Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease
TLDR
Analysis of cerebrospinal fluid (CSF) collected longitudinally in research participants in the Dominantly Inherited Alzheimer Network (DIAN), a multicenter, international biomarker study of ADAD, revealed reductions in amyloid-β1–42 (indicating the presence ofAmyloid plaques) and increases in markers of neuronal injury (tau, ptau181, and VILIP-1) in mutation carriers during the early presymptomatic stage.
Association of Cerebral Amyloid-&bgr; Aggregation With Cognitive Functioning in Persons Without Dementia
TLDR
Low cognitive scores had limited utility for screening of amyloid positivity in persons with normal cognition and those with MCI and their value as a screening measure for early AD among persons without dementia is limited.
Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction
TLDR
Neuroimaging and cerebrospinal fluid analyses in humans reveal that loss of blood–brain barrier integrity and brain capillary pericyte damage are early biomarkers of cognitive impairment that occur independently of changes in amyloid-β and tau.
Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis
TLDR
The value of an ultrasensitive single‐molecule array (Simoa) serum NfL (sNfL) assay in multiple sclerosis (MS) is explored.
Changes in Amyloid-β and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein
TLDR
Mechanistically, these results suggest that Aβ deposition in the brain may be the driving force for changes in Aβ and Tau in the CSF of AD patients, and suggest the translational value of APP mouse models for understanding events in human disease.
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease
TLDR
Serum NfL dynamics in serum predict disease progression and brain neurodegeneration at the early presymptomatic stages of familial Alzheimer’s disease, which supports its potential utility as a clinically useful biomarker.
...
1
2
3
...